We presented our experience from 1975 to 1994 with emphasis on the long term follow-up of children with optic chiasm astrocytomas in part I. In part II we describe the surgical management of 20 patients with the diagnosis of an astrocytoma of the optic chiasm confirmed by biopsy. These patients underwent surgery by the senior author between 1988 and 1994. The patients and the tumors in this series are comparable in age, sex, and presentation and imaging characteristics to other series. Surgery was undertaken with the intent to reduce tumor volume and mass effect and in certain cases to confirm the diagnosis. The patients’ mean age at the time of surgery was 81 (range 18–216) months. The surgical approaches used were pterional in 11 patients, transorbital/subfrontal in 8, and subfrontal in 1 patient. Greater than 50% of the tumor was resected in 8 patients, less than 50% was resected in 9, and biopsy only was achieved in 3 patients. Larger tumors were more likely to have magnetic resonance imaging documented debulking of tumor. Permanent morbidity included mild visual loss, diabetes insipidus, mild hemiparesis, and panhypopituitarism in 1 patient each. There was no surgical mortality. The likelihood of resecting greater than 50% of the tumor was higher in those with a diameter greater than 25 mm. The indications for craniotomy are (1) to debulk symptomatic tumors greater than 50 mm in diameter which are exophytic or cystic; (2) to relieve obstruction at the foramen of Monro, and (3) for diagnostic biopsy.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.